Preparation and characterisation of a novel nanoparticle for delivery of oxaliplatin

LI Lewei; LI Jinhui; PENG Xingcheng; LIU Yi; TAO Xiaojun; HE Chunlian

PDF(4434 KB)

Journal of Hunan Normal University(Medical Science) ›› 2025, Vol. 22 ›› Issue (3) : 134-141.

Pharmacy

Preparation and characterisation of a novel nanoparticle for delivery of oxaliplatin

LI Lewei¹, LI Jinhui², PENG Xingcheng¹, LIU Yi¹, TAO Xiaojun¹, HE Chunlian¹

Author information +

History +

Abstract

Objective Design and preparation of a novel poly (lysine) amphiphilic polymer nanodelivery system for oxaliplatin (OXA) delivery to achieve improved efficacy and target site drug release rate. Methods The mPssPC polymers were prepared by chemical synthesis, and the successful synthesis of the polymers was confirmed by infrared spectroscopy and nuclear magnetic resonance hydrogen spectroscopy. The mPssPC NPs and mPssPC-OXA NPs were prepared by physical embedding and self-assembly, and the physicochemical properties of the nanoparticles were characterized by dynamic light scattering analysis, transmission electron microscopy observation, stability test and in vitro drug release assay. The cytotoxicity, cellular uptake, and immune escape effects of mPssPC-OXA NPs were tested by in vitro cellular assays. Results mPssPC NPs and mPssPC-OXA NPs were successfully prepared. mPssPC NPs had a small particle size (190.77±2.91 nm), positive charge (43.20±0.72 mV), and excellent stability. mPssPC-OXA NPs showed a spherical shape with regular shape under transmission electron microscopy, and the drug release of mPssPC-OXA NPs was characterised by slow release and GSH-sensitive drug release. In in vitro cellular studies, mPssPC-OXA NPs were effectively taken up by HCT-116 cells and significantly inhibited tumor cell activity, and also effectively reduced phagocytic clearance of nanoparticles by RAW264.7 cells. Conclusion The mPssPC-OXA NPs constructed with polylysine as the basic backbone promoted drug uptake in tumor cells, which significantly increased cytotoxicity. Meanwhile, mPssPC-OXA NPs could achieve immune escape and more and faster drug release in a high glutathione concentration environment, achieving the effect of increasing the drug concentration at the target site.

Key words

poly (lysine) / oxaliplatin / HCT-116 cells / nanoparticle

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LI Lewei, LI Jinhui, PENG Xingcheng, LIU Yi, TAO Xiaojun, HE Chunlian. Preparation and characterisation of a novel nanoparticle for delivery of oxaliplatin[J]. Journal of Hunan Normal University(Medical Science). 2025, 22(3): 134-141

References

[1] ZHANG Q, ZHOU Y, FENG X, et al.Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer[J]. Biomed Pharmacother, 2022, 153: 113426.
[2] GU Z, HAO Y, SCHOMANN T, et al.Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation[J]. J Control Release, 2023, 357: 531-544.
[3] FAKHR E, ZARE F, AZADMANESH K, et al.LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan[J]. Biomed Pharmacother, 2021, 143: 112091.
[4] MAHAKI H, MANSOURIAN M, MESHKAT Z, et al.Nanoparticles Containing Oxaliplatin and the Treatment of Colorectal Cancer[J]. Curr Pharm Des, 2023, 29(38): 3018-3039.
[5] LI Y, SUN Z, CUI Y, et al.Oxaliplatin derived monofunctional triazole-containing platinum (II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer[J]. Bioorg Chem, 2021, 107: 104636.
[6] CHEN S, SONG Z, FENG R.Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel[J]. Anticancer Agents Med Chem, 2020, 20(18): 2169-2189.
[7] LAN M, LU W, ZOU T, et al.Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy[J]. Cell Mol Life Sci, 2021, 78(5): 2105-2129.
[8] LIU Z, CHU W, SUN Q, et al.Micelle-contained and PEGylated hybrid liposomes of combined gemcitabine and cisplatin delivery for enhancing antitumor activity[J]. Int J Pharm, 2021, 602: 120619.
[9] MALEKI H, HOSSEINI NAJAFABADI M R, WEBSTER T J, et al. Effect of Paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma[J]. Int J Pharm, 2021, 604: 120722.
[10] SUN Y, MA X, HU H.Marine Polysaccharides as a Versatile Biomass for the Construction of Nano Drug Delivery Systems[J]. Mar Drugs, 2021, 19(6): 345.
[11] ZHU Y, WEN L M, LI R, et al.Recent advances of nano-drug delivery system in oral squamous cell carcinoma treatment[J]. Eur Rev Med Pharmacol Sci, 2019, 23(21): 9445-9453.
[12] HAN S, LIU Y, NIE X, et al.Efficient delivery of antitumor drug to the nuclei of tumor cells by amphiphilic biodegradable poly (L-aspartic acid-co-lactic acid) /DPPE co-polymer nanoparticles[J]. Small, 2012, 8(10): 1596-1606.
[13] LIU X, WU Z, GUO C, et al.Hypoxia responsive nano-drug delivery system based on angelica polysaccharide for liver cancer therapy[J]. Drug Deliv, 2022, 29(1): 138-148.
[14] BURGER H, LOOS W J, EECHOUTE K, et al.Drug transporters of platinum-based anticancer agents and their clinical significance[J]. Drug Resist Updat, 2011, 14(1): 22-34.
[15] FU R, ZHAO B, CHEN M, et al.Moving beyond cisplatin resistance: mechanisms, challenges, and prospects for overcoming recurrence in clinical cancer therapy[J]. Med Oncol, 2023, 41(1): 9.
[16] ALIREZALU K, HESARI J, YAGHOUBI M, et al.Combined effects of ε-polylysine and ε-polylysine nanoparticles with plant extracts on the shelf life and quality characteristics of nitrite-free frankfurter-type sausages[J]. Meat Sci, 2021, 172: 108318.
[17] DU X, YIN S, XU L, et al.Polylysine and cysteine functionalized chitosan nanoparticle as an efficient platform for oral delivery of paclitaxel[J]. Carbohydr Polym, 2020, 229: 115484.
[18] FAN D, CAO Y, CAO M, et al.Nanomedicine in cancer therapy[J]. Signal Transduct Target Ther, 2023, 8(1): 293.
[19] MAININI F, ECCLES M R.Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy[J]. Molecules, 2020, 25(11): 2692.
[20] IKEDA-IMAFUKU M, WANG L L, RODRIGUES D, et al.Strategies to improve the EPR effect: A mechanistic perspective and clinical translation[J]. J Control Release, 2022, 345: 512-536.
[21] JIN Q, DENG Y, CHEN X, et al.Rational Design of Cancer Nanomedicine for Simultaneous Stealth Surface and Enhanced Cellular Uptake[J]. ACS Nano, 2019, 13(2): 954-977.
[22] BRÜLISAUER L, GAUTHIER M A, LEROUX J C. Disulfide-containing parenteral delivery systems and their redox-biological fate[J]. J Control Release, 2014, 195: 147-154.
[23] FUKUMURA D, JAIN R K.Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize[J]. J Cell Biochem, 2007, 101(4): 937-949.
[24] YIN T, WU Q, WANG L, et al.Well-Defined Redox-Sensitive Polyethene Glycol-Paclitaxel Prodrug Conjugate for Tumor-Specific Delivery of Paclitaxel Using Octreotide for Tumor Targeting[J]. Mol Pharm, 2015, 12(8): 3020-3031.
[25] TENCHOV R, SASSO J M, ZHOU Q A.PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective[J]. Bioconjug Chem, 2023, 34(6): 941-960.
[26] FAM S Y, CHEE C F, YONG C Y, et al.Stealth Coating of Nanoparticles in Drug-Delivery Systems[J]. Nanomaterials (Basel), 2020, 10(4): 787.
[27] LAMMERS T.Macro-nanomedicine: Targeting the big picture[J]. J Control Release, 2019, 294: 372-375.
[28] PARK K.The beginning of the end of the nanomedicine hype[J]. J Control Release, 2019, 305: 221-222.